Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss
NCT ID: NCT06878599
Last Updated: 2025-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
70 participants
INTERVENTIONAL
2025-05-01
2028-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To compare outcomes of intratympanic injection of dexamethasone and hyaluronic acid mixture to dexamethasone alone in treatment of SSNHL.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss
NCT00335920
Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT05786378
Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01588925
Sudden Hearing Loss Multi-center Clinical Trial
NCT02026479
Intracochlear Injection of Glucocorticoid
NCT07134075
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intratympanic (IT) dexamethasone application has shown significantly higher perilymph steroid concentrations with lower systemic concentrations, thus avoiding the side effects associated with the systemic route. It has been used with varying results for the treatment of Meniere's disease, SSNHL, low frequency hearing loss and tinnitus. After IT injection, the drug concentration in the inner ear depends on the drug being in contact with the round window membrane (RWM), absorbing it from the middle ear into the inner ear. However, large amount of the injected drugs are either absorbed by the middle ear mucosa or evacuated via the eustachian tube.
It has been postulated that combining the drug with a biodegradable material will prolong its availability in the middle ear and/or aid its diffusion across the RWM. Between these materials, Hyaluronic acid (HA) is a natural product normally present is humans' perilymph in small amounts along with many other tissues throughout the body. Several postulations have been given to HA mechanism of action in drug delivery in the middle ear either by its osmotic effect on the perilymph, modulating RWM permeability or altering blood viscosity thus increasing blood and oxygen delivery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hyalouronic acid with dexamethasone injection
Intratympanic injection
Hyaluronic Acid (HA)
Adding Hyaluronic acid to dexamethasone as intratympanic injection
Dexamethasone
Intratympanic injection of Dexamethasone
Dexamethasone injection
Intratympanic injection
Dexamethasone
Intratympanic injection of Dexamethasone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hyaluronic Acid (HA)
Adding Hyaluronic acid to dexamethasone as intratympanic injection
Dexamethasone
Intratympanic injection of Dexamethasone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with sudden sensory neural hearing loss (SSNHL)
Exclusion Criteria
2. Patient with history of traumatic skull base fracture.
3. Patients with previous ear surgery.
4. Patients with other neurological symptoms or signs (Other cranial nerves affection).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mai Essam Ali AbuElmagd
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut University Hospital
Asyut, Asyut Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hyaluronic acid in SSNHL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.